Hematological Oncology最新文献

{"title":"Post-CAR T-Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B-Cell Lymphoma","authors":"Hazim S. Ababneh,&nbsp;Matthew J. Frigault,&nbsp;Andrea K. Ng,&nbsp;Chirayu G. Patel","doi":"10.1002/hon.70025","DOIUrl":"10.1002/hon.70025","url":null,"abstract":"<div>\u0000 \u0000 <p>18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) parameters have shown a significant prognostic role in relapsed/refractory large B-cell lymphoma (LBCL) patients undergoing CD19-targeted chimeric antigen receptor (CAR) T-cell therapy. While a substantial body of evidence exists on the prognostic value of PET/CT parameters in peri-CAR T setting, data available on the prognostic value of PET/CT parameters following CAR T-cell therapy failure is lacking. Therefore, we sought to analyze the PET/CT scans of LBCL patients who experienced post-CAR T relapsed/progressive disease and subsequently received salvage therapies. Thirty-three LBCL patients who had PET-CT scans done demonstrating post-CAR T failure and then received salvage therapies [as a first salvage modality: RT alone, nine patients; combined modality therapy (CMT), seven patients; systemic therapy (ST) alone, 17 patients] were analyzed. The median follow-up after CAR T-cell infusion was 11.7 months [interquartile range (IQR): 5.1–24.4 months], and the median follow-up after post-CAR T salvage therapy was 7.3 months (IQR: 2.7–19.1 months). The median timeframe for the PET scan showing post-CAR T failure was 2.4 months (IQR: 0.96–5.0 months). On univariable analysis from salvage therapy start date, high metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were associated with inferior overall survival (OS) (Hazard ratio –HR = 8.4, <i>p</i> &lt; 0.0001; HR = 3.2, <i>p</i> = 0.01, respectively). High MTV was associated with a non-significant trend of inferior progression-free survival (PFS) (HR = 3.5, <i>p</i> = 0.09). High maximum standardized uptake value (SUVmax) was not associated with inferior OS or inferior PFS. On multivariable analysis from salvage therapy start date, high MTV (HR = 4.6, 95% CI: 1.5–14.3, <i>p</i> = 0.009) was identified to be an independent prognostic factor for inferior OS. High International Prognostic Index (IPI) (≥ 3) at the time of salvage therapy (HR = 2.5, 95% CI: 1.1–5.6, <i>p</i> = 0.02) was significantly associated with inferior PFS. Our study shows that semiquantitative PET/CT metrics, especially MTV, are significant prognostic indicators of overall survival in this highly refractory population after CAR T-cell therapy failure, potentially refining prognostic and treatment approaches beyond conventional parameters like IPI.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142835284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combining Total Metabolic Tumor Volume With Beta-2-Microglobulin Levels Predicts Outcomes in High-Burden Follicular Lymphoma Patients","authors":"A. Zduniak,&nbsp;E. Lévêque,&nbsp;S. Draye-Carbonnier,&nbsp;S. Becker,&nbsp;D. Tonnelet,&nbsp;S. Dubois,&nbsp;P. Vera,&nbsp;H. Tilly,&nbsp;F. Jardin,&nbsp;P. Decazes,&nbsp;V. Camus","doi":"10.1002/hon.70010","DOIUrl":"10.1002/hon.70010","url":null,"abstract":"<p>We aimed to explore the predictive value of total metabolic tumor volume (TMTV) and beta-2-microglobulin (B2M) levels in patients with follicular lymphoma (FL) with a high tumor burden receiving standard first-line immunochemotherapy. We analyzed 125 patients with the following characteristics: median age, 61 years (55; 67), advanced-stage disease, 88.8%; high FLIPI, 49.6%; TMTV, &gt; 510 cm³; B2M, &gt; 3 mg/L (24.8%); and R-CHOP-like treatment, 86.4%. We defined the following categories: low-risk (36%), TMTV ≤ 510 cm³ and B2M ≤ 3 mg/L; intermediate-risk (45.6%), TMTV &gt; 510 cm³ or B2M &gt; 3 mg/L; and high-risk (18.4%), TMTV &gt; 510 cm³ and B2M &gt; 3 mg/L. The 5-year overall survival rates were estimated to be 96.1%, 89.1% and 73.7% for low-, intermediate- and high-risk patients, respectively (<i>p</i> = 0.003). Patients at intermediate and high risk according to the TMTV/B2M score were at high risk of disease progression within 24 months of treatment initiation (HR = 2.45 [95% CI: 1.23–4.85] and HR = 3.75 [95% CI: 1.7–8.2], respectively). This TMTV/B2M score may identify patients with the highest unmet medical needs.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Outcomes of Reduced-Toxicity Conditioning Using 8-Gray Total Body Irradiation, Fludarabine, and Cyclophosphamide in Children, Adolescents, and Young Adults With Hematological Malignancies","authors":"Hirokazu Morokawa,&nbsp;Koichi Hirabayashi,&nbsp;Yu Furui,&nbsp;Eri Okura,&nbsp;Shoji Saito,&nbsp;Yozo Nakazawa","doi":"10.1002/hon.70026","DOIUrl":"10.1002/hon.70026","url":null,"abstract":"<p>Recent studies have indicated that total body irradiation (TBI)-based reduced-toxicity conditioning (RTC) may be a potential treatment modality, especially in adults with leukemia. However, its efficacy and safety in children with hematological malignancies remain unclear. To investigate the long-term outcomes and safety of allogeneic hematopoietic stem cell transplantation (allo-HSCT) using an 8-Gray (Gy) TBI/fludarabine (FLU)/cyclophosphamide (CY) RTC in children with hematological malignancies. We included 66 consecutive patients with leukemia, lymphoma, or myelodysplastic syndrome in this retrospective cohort study. Participants were &lt; 25 years old and received an 8-Gy TBI/FLU/CY RTC regimen followed by the first allo-HSCT at Shinshu University Hospital between March 2004 and March 2021. The 5-year overall and relapse-free survival probabilities were 88.2% and 76.5%, respectively, in the lymphoid malignancy group. The myeloid malignancy group had probabilities of 72.4% and 58.6%, respectively. The 5-year cumulative incidences of relapse and non-relapse mortality were 20.6% and 2.9%, respectively, in the lymphoid malignancy group. These incidences were 37.9% and 3.4%, respectively, in the myeloid malignancy group. All patients had engraftment without early relapse and none developed grade 5 regimen-related toxicity within 28 days after allo-HSCT. Nonetheless, two patients had congenital abnormalities caused by chromosomal aberrations and died without relapse. 8-Gy TBI/FLU/CY RTC was safe in children with hematological malignancies, regardless of the donor source. However, safety concerns were noted in cases of chromosomal aberration-induced congenital abnormalities. Additionally, patients in the lymphoid and myeloid malignancy groups had favorable prognoses.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11646108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ceiling Effect of International Myeloma Working Group Frailty Score in Real-World Population of Older Adults With Cancer","authors":"Carla T. Williams,&nbsp;Cenk Yildirim,&nbsp;Mayuri Dharne,&nbsp;Maya M. Abdallah,&nbsp;Jane A. Driver,&nbsp;Nikhil C. Munshi,&nbsp;Nathanael R. Fillmore,&nbsp;Clark DuMontier","doi":"10.1002/hon.70016","DOIUrl":"10.1002/hon.70016","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospital Palliative Care Team Consultations in Different Subgroups of Hematologic Malignancies","authors":"Anja M. Caspers,&nbsp;Anne Pralong,&nbsp;Michael Hallek,&nbsp;Raymond Voltz,&nbsp;Steffen T. Simon,&nbsp;Dennis A. Eichenauer","doi":"10.1002/hon.70021","DOIUrl":"10.1002/hon.70021","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Situ Tracking of TCRβ Isoforms for Detection of T Cell Clonality: Implication for Precision Diagnosis and Targeted Immunotherapy of T-Cell Neoplasms","authors":"Marie Therese Manipadam,&nbsp;Andrea Marra,&nbsp;Alan Ramsay,&nbsp;Sugerdana Padmasri,&nbsp;Adheesh Gosh,&nbsp;Margarida Neves,&nbsp;Chris Bailey,&nbsp;Sabine Pomplun,&nbsp;Paul Maciocia,&nbsp;Kate Cwynarski,&nbsp;Mathieu Ferrari,&nbsp;Pierre Lao-Siriex,&nbsp;Miguel Piris,&nbsp;Brunangelo Falini,&nbsp;David Linch,&nbsp;Andreas Rosenwald,&nbsp;Martin Pule,&nbsp;Alberto Zamò,&nbsp;Teresa Marafioti","doi":"10.1002/hon.70018","DOIUrl":"10.1002/hon.70018","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breaking Traditions: Evaluating Single Fraction Radiation in Indolent Lymphoma","authors":"Hazim S. Ababneh,&nbsp;Chirayu G. Patel","doi":"10.1002/hon.70015","DOIUrl":"10.1002/hon.70015","url":null,"abstract":"<div>\u0000 \u0000 <p>As indolent non-Hodgkin's lymphomas (iNHLs) are very radiosensitive, radiation treatment (RT) has been established as an essential curative and palliative modality for early and advanced stages of the disease. Several studies have explored the role of very low-dose RT for palliation in indolent non-Hodgkin's lymphomas, demonstrating that this approach can lead to high rates of local control, and thereby, help improve the quality of life for these patients. While the most common schedule of very low-dose RT used in the palliative setting is 4Gy in 2 fractions, which was established in the landmark FoRT trial, this requires patients to be available for two RT sessions, increasing the financial and opportunity costs for the patient. Currently, data regarding the use of a single fraction of very low-dose RT (4Gy) for treating iNHLs in the palliative setting is still lacking. In this viewpoint, we aim to draw attention to this approach, where we emphasize the need for further exploration of the single-dose fractionation schedule as a non-toxic, simple, and easy treatment approach for iNHLs, which would inform future clinical trials to investigate this dose/fractionation.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study","authors":"Peiqi Zhao,&nbsp;Shu Zhao,&nbsp;Chen Huang,&nbsp;Yajun Li,&nbsp;Jiesong Wang,&nbsp;Junqing Xu,&nbsp;Lanfang Li,&nbsp;Zhengzi Qian,&nbsp;Wei Li,&nbsp;Shiyong Zhou,&nbsp;Lihua Qiu,&nbsp;Xianming Liu,&nbsp;Ying Chen,&nbsp;Yanan Jiang,&nbsp;Yanbin Zheng,&nbsp;Daoguang Chen,&nbsp;Hui Zhou,&nbsp;Yuhuan Gao,&nbsp;Qingyuan Zhang,&nbsp;Huilai Zhang","doi":"10.1002/hon.70017","DOIUrl":"10.1002/hon.70017","url":null,"abstract":"<div>\u0000 \u0000 <p>Polatuzumab vedotin plus R-CHP (Pola-R-CHP) is approved as a new standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) based on the POLARIX trial. However, real-world data on its efficacy and safety in unselected patients is lacking. We conducted a retrospective cohort study to evaluate Pola-R-CHP versus R-CHOP outcomes in routine clinical practice in China. This is a multi-institutional retrospective cohort study and included all consecutive patients that received at least one dose of polatuzumab vedotin up until February 2024. A total of 600 eligible patients from 6 centers were identified, 131 receiving Pola-R-CHP and 469 R-CHOP. After 1:2 propensity score matching, 128 pairs were obtained for further survival and prognosis analysis. With a median follow-up of 12.8 months, 12-month progression-free survival (PFS) was numerically higher with Pola-R-CHP versus R-CHOP (90.3% vs. 84.1%, <i>p</i> = 0.18). Benefits were consistently observed across molecular subgroups, especially advanced stage, ECOG ≥ 2, extranodal involvement ≥ 2 and non-GCB group. The complete response rate of the Pola-R-CHP group was higher than that of the RCHOP group (86.8% vs. 79.7%; <i>p</i> = 0.09), but there was no statistical difference. Safety profiles were comparable, with no new concerns. Among 128 patients treated with Pola-R-CHP, 96 underwent gene sequencing analysis: MCD (25.0%), EZB (13.5%), combined subtype (12.5%), ST2 (9.4%), and other/unclassifiable subtype (30.2%). The most common mutations (&gt; 25% of cases) were PIM1, TP53, BCL-6, KMT2D, SOCS1, BCL-2. Genetic testing results show the correlation between genotyping, gene mutations in PIM1/TP53 and therapeutic efficacy. This large real-world study supports Pola-R-CHP as an effective frontline option for DLBCL, with sustained efficacy versus R-CHOP observed in unselected populations. While 12-month PFS failed to reach statistical significance, subgroup analyses favor Pola-R-CHP. Further research with a wider population, longer follow-up, and screening of advantageous groups are warranted.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease","authors":"Carola Riva,&nbsp;Paola Minetto,&nbsp;Maria Chies,&nbsp;Chiara Vernarecci,&nbsp;Nicoletta Colombo,&nbsp;Sara Rosellini,&nbsp;Alessia Parodi,&nbsp;Elisabetta Tedone,&nbsp;Enrico Carminati,&nbsp;Clara Nurra,&nbsp;Francesco Puglisi,&nbsp;Michela Frello,&nbsp;Elena Maio,&nbsp;Beatrice Ferro,&nbsp;Giada Zecchetti,&nbsp;Giuseppina Fugazza,&nbsp;Paolo Nozza,&nbsp;Michele Cea,&nbsp;Roberto Massimo Lemoli,&nbsp;Fabio Guolo","doi":"10.1002/hon.70005","DOIUrl":"10.1002/hon.70005","url":null,"abstract":"<div>\u0000 \u0000 <p>Secondary acute myeloid leukemia (s-AML) is associated with inferior outcomes with conventional chemotherapy, and fludarabine combinations (FLAG-Ida) have been tested to improve results. More recently, CPX-351 resulted superior to conventional 3 + 7 in s-AML patients. In the UK NCRI AML19 trial, AML patients were randomized to receive either FLAG-Ida or CPX-351. Subgroup analysis revealed better overall survival (OS) with CPX-351 in patients with MDS-related gene mutations. Unfortunately, minimal residual disease (MRD) was evaluated only in a minority of patients. The aim of this study was to further disclose the mechanisms of higher efficacy of CPX-351 in s-AML, with a focus on MRD. We analyzed 183 consecutive s-AML elderly patients (median age 69, range 60–77) treated with CPX-351 (<i>n</i> = 82) or receiving FLAG-Ida (<i>n</i> = 101). Complete remission (CR) rate and MRD negativity probability were higher among patients receiving CPX-351 (MRD negative CR rate of 40/64, 62.5%, compared to 25/55, 45% in patients who received FLAG-Ida, <i>p</i> &lt; 0.05). Extra-hematological toxicity was lower in CPX-351 arm, and 30 days mortality was 3.6% and 8% in patients receiving CPX-351 or FLAG-Ida, respectively. Notably, 21/64 (32.8%) CR patients treated with CPX 351 underwent allogeneic stem cell transplantation (HSCT), compared to 5/55 with FLAG-Ida (9%, <i>p</i> &lt; 0.05). Overall, CPX-351 treatment resulted in higher OS (median OS 17.7 vs. 11.2 months with FLAG-Ida, <i>p</i> &lt; 0.05). The better outcome of CPX-351 compared to FLAG-Ida in our cohort may be explained by a greater probability of MRD negativity, alongside with an improved tolerance, enabling more s-AML patients to undergo HSCT.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological Characteristics of Extranodal Marginal Zone Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT-Lymphoma) of the Intestine: A Single Center Analysis","authors":"Oskar Steinbrecher,&nbsp;Barbara Kiesewetter,&nbsp;Werner Dolak,&nbsp;Rosa Brand,&nbsp;Ingrid Simonitsch-Klupp,&nbsp;Markus Raderer","doi":"10.1002/hon.70007","DOIUrl":"https://doi.org/10.1002/hon.70007","url":null,"abstract":"<p>Extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT-lymphoma) is an indolent B-cell lymphoma with a distinct affinity for mucosal structures. Most commonly arising in the stomach, only roughly 2% of MALT-lymphomas occur in the colon or the intestine. In view of this, we have retrospectively assessed all patients with MALT-lymphoma involving the intestine for clinicopathological characteristics. Data of all patients with MALT-lymphoma and intestinal involvement (i.e. both primary and secondary), treated and followed at the Medical University of Vienna between 1999 and 2021 were retrospectively collected from hospital records and analyzed. Differences in baseline and therapy characteristics, as well as survival between primary and secondary, and between intestinal and gastric MALT-lymphoma (as the most common subgroup of patients) were investigated. In total, 42 patients were identified; 24/484 (5%) were classified as primary and 18 (3.7%) as secondary intestinal MALT-lymphomas. The most common primary intestinal location was the colon (10/24) and the most frequent primary site in the 18 cases with secondary intestinal MALT-lymphomas was the stomach (14/18). A total of 28/42 (66.7%) patients presented with LUGANO stage I, 7/42 (16.7%) with stage II/IIE and 7/42 (16.7%) with stage IV disease. Translocation t (11; 18) (q21; q21) was positive in 47% of patients with secondary and 25% of primary intestinal MALT-lymphomas. Median OS in for intestinal MALT-lymphoma was 301 months (95% CI n.a.) with 89.1% alive at 5 years and 77.2% alive at 10 years. Median PFS in the entire cohort was 50.4 months (95% CI 38.4–62.4 months), with an overall response rate and disease control rate of 73% and 97.3%, respectively. No difference in OS and PFS between primary and secondary intestinal, as well as between intestinal and gastric MALT-lymphoma was detected. Our data suggest that dissemination within the GI tract does not seem to be an adverse prognostic feature and highlights the preferred use of the Lugano staging system in such patients, which also summarizes multiple lesions within the GI-tract as Stage I.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142763952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}